This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nowak, M. Articles by Fruchart, J.-C. Search for Related Content PubMed PubMed Citation Articles by Nowak, M. Articles by Fruchart, J.-C.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, February 2005, p. 1537-1548, Vol. 25, No. 4
0270-7306/05/$08.00+0     doi:10.1128/MCB.25.4.1537-1548.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor

Département d'Athérosclérose, UR 545 INSERM, Institut Pasteur de Lille et Université de Lille II, Lille,¹ Genfit SA, Loos, France,² Genome Sciences Department and Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, California,³ Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland⁴

Received 8 October 2004/ Accepted 8 November 2004

The apolipoprotein A5 gene (APOA5) has been repeatedly implicated in lowering plasma triglyceride levels. Since several studies have demonstrated that hyperinsulinemia is associated with hypertriglyceridemia, we sought to determine whether APOA5 is regulated by insulin. Here, we show that cell lines and mice treated with insulin down-regulate APOA5 expression in a dose-dependent manner. Furthermore, we found that insulin decreases human APOA5 promoter activity, and subsequent deletion and mutation analyses uncovered a functional E box in the promoter. Electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrated that this APOA5 E box binds upstream stimulatory factors (USFs). Moreover, in transfection studies, USF1 stimulates APOA5 promoter activity, and the treatment with insulin reduced the binding of USF1/USF2 to the APOA5 promoter. The inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway abolished insulin's effect on APOA5 gene expression, while the inhibition of the P70 S6 kinase pathway with rapamycin reversed its effect and increased APOA5 gene expression. Using an oligonucleotide precipitation assay for USF from nuclear extracts, we demonstrate that phosphorylated USF1 fails to bind to the APOA5 promoter. Taken together, these data indicate that insulin-mediated APOA5 gene transrepression could involve a phosphorylation of USFs through the PI3K and P70 S6 kinase pathways that modulate their binding to the APOA5 E box and results in APOA5 down-regulation. The effect of exogenous hyperinsulinemia in men showed a decrease in the plasma ApoAV level. These results suggest a potential contribution of the APOA5 gene in hypertriglyceridemia associated with hyperinsulinemia.

This article has been cited by other articles:

• Holzapfel, C, Baumert, J, Grallert, H, Muller, A M, Thorand, B, Khuseyinova, N, Herder, C, Meisinger, C, Hauner, H, Wichmann, H E, Koenig, W, Illig, T, Klopp, N (2008). Genetic variants in the USF1 gene are associated with low-density lipoprotein cholesterol levels and incident type 2 diabetes mellitus in women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur J Endocrinol 159: 407-416 [Abstract] [Full Text]  
• Paquette, J., Bessette, B., Ledru, E., Deal, C. (2007). Identification of Upstream Stimulatory Factor Binding Sites in the Human IGFBP3 Promoter and Potential Implication of Adjacent Single-Nucleotide Polymorphisms and Responsiveness to Insulin. Endocrinology 148: 6007-6018 [Abstract] [Full Text]  
• Pezzolesi, M. G., Zbuk, K. M., Waite, K. A., Eng, C. (2007). Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Hum Mol Genet 16: 1058-1071 [Abstract] [Full Text]  
• Peltonen, L., Perola, M., Naukkarinen, J., Palotie, A. (2006). Lessons from studying monogenic disease for common disease.. Hum Mol Genet 15: R67-R74 [Full Text]  
• Ruiz-Narvaez, E. A., Yang, Y., Nakanishi, Y., Kirchdorfer, J., Campos, H. (2005). APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J. Lipid Res. 46: 2605-2613 [Abstract] [Full Text]  
• Rada-Iglesias, A., Wallerman, O., Koch, C., Ameur, A., Enroth, S., Clelland, G., Wester, K., Wilcox, S., Dovey, O. M., Ellis, P. D., Wraight, V. L., James, K., Andrews, R., Langford, C., Dhami, P., Carter, N., Vetrie, D., Ponten, F., Komorowski, J., Dunham, I., Wadelius, C. (2005). Binding sites for metabolic disease related transcription factors inferred at base pair resolution by chromatin immunoprecipitation and genomic microarrays. Hum Mol Genet 14: 3435-3447 [Abstract] [Full Text]  
• Jiang, B., Mendelson, C. R. (2005). O2 Enhancement of Human Trophoblast Differentiation and hCYP19 (Aromatase) Gene Expression Are Mediated by Proteasomal Degradation of USF1 and USF2. Mol. Cell. Biol. 25: 8824-8833 [Abstract] [Full Text]  
• Abdelmegeed, M. A., Carruthers, N. J., Woodcroft, K. J., Kim, S. K., Novak, R. F. (2005). Acetoacetate Induces CYP2E1 Protein and Suppresses CYP2E1 mRNA in Primary Cultured Rat Hepatocytes. J. Pharmacol. Exp. Ther. 315: 203-213 [Abstract] [Full Text]  
• Ishihara, M., Kujiraoka, T., Iwasaki, T., Nagano, M., Takano, M., Ishii, J., Tsuji, M., Ide, H., Miller, I. P., Miller, N. E., Hattori, H. (2005). A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J. Lipid Res. 46: 2015-2022 [Abstract] [Full Text]  
• Naukkarinen, J., Gentile, M., Soro-Paavonen, A., Saarela, J., Koistinen, H. A., Pajukanta, P., Taskinen, M.-R., Peltonen, L. (2005). USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet 14: 2595-2605 [Abstract] [Full Text]  
• Hoffstedt, J., Ryden, M., Wahrenberg, H., van Harmelen, V., Arner, P. (2005). Upstream Transcription Factor-1 Gene Polymorphism Is Associated with Increased Adipocyte Lipolysis. J. Clin. Endocrinol. Metab. 90: 5356-5360 [Abstract] [Full Text]  
• Huertas-Vazquez, A., Aguilar-Salinas, C., Lusis, A. J., Cantor, R. M., Canizales-Quinteros, S., Lee, J. C., Mariana-Nunez, L., Riba-Ramirez, R.-M. L., Jokiaho, A., Tusie-Luna, T., Pajukanta, P. (2005). Familial Combined Hyperlipidemia in Mexicans: Association With Upstream Transcription Factor 1 and Linkage on Chromosome 16q24.1. Arterioscler. Thromb. Vasc. Bio. 25: 1985-1991 [Abstract] [Full Text]  
• Schultze, A. E., Alborn, W. E., Newton, R. K., Konrad, R. J. (2005). Administration of a PPAR{alpha} agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res. 46: 1591-1595 [Abstract] [Full Text]  
• Prieur, X., Huby, T., Coste, H., Schaap, F. G., Chapman, M. J., Rodriguez, J. C. (2005). Thyroid Hormone Regulates the Hypotriglyceridemic Gene APOA5. J. Biol. Chem. 280: 27533-27543 [Abstract] [Full Text]